CEO and Board Director
LianBio
LianBio is focused on developing and expediting the availability of novel therapeutics for patients in China, specifically targeting unmet medical needs in various disease areas. The company is currently winding down operations and pursuing the sale of its remaining pipeline assets.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$310MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
LianBio was focused on addressing unmet medical needs in China by developing and commercializing novel therapeutics across various disease areas.
Solution
LianBio aimed to accelerate the availability of new treatments for patients in China. The company focused on identifying and developing promising therapies to address specific medical needs within the Chinese market. However, the company is currently winding down operations and seeking to sell its remaining pipeline assets.
Target Audience
The company's original target audience was patients in China with unmet medical needs and the healthcare providers who treat them.
Features
- Focused on developing therapeutics for the Chinese market.
- Targeted unmet medical needs across various disease areas.
- Pipeline assets are currently for sale.